The Hollywood Stack combines GLP-1 weight loss, GH axis optimization, and testosterone support into one comprehensive body recomposition protocol. Full guide with lab tracking.
Quick Summary - The Hollywood Stack targets three independent axes simultaneously: metabolic (GLP-1), GH (GHRH), and HPG (testosterone) - Each compound addresses a different pathway with no competition between mechanisms - Comprehensive lab monitoring is non-negotiable -- this stack affects multiple hormonal systems - Track at minimum: IGF-1, testosterone panel, HbA1c, fasting glucose, ApoB, and liver enzymes - This is an advanced stack -- not recommended for first-time peptide users
The name "Hollywood Stack" emerged from online longevity communities referring to the combination of compounds increasingly used by actors, executives, and performance-focused individuals seeking dramatic body recomposition in defined timeframes.
The stack has a logical physiological basis. Body composition is governed by three primary hormonal systems: metabolic regulation (insulin sensitivity, fat storage, appetite), the growth hormone axis (lean mass preservation, fat metabolism, IGF-1), and the HPG axis (testosterone, muscle protein synthesis, energy). These systems interact -- optimizing all three simultaneously produces results that optimizing any one alone cannot.
The Hollywood Stack targets all three:
Semaglutide (or tirzepatide) addresses the metabolic and appetite axis -- reducing caloric intake through appetite suppression, improving insulin sensitivity, and driving visceral fat reduction.
Tesamorelin (or ipamorelin plus CJC-1295) addresses the GH axis -- preserving and building lean mass while fat is lost, raising IGF-1 to youthful ranges, and specifically reducing visceral adipose tissue which semaglutide does not fully address.
Enclomiphene addresses the HPG axis -- maintaining or elevating endogenous testosterone during the caloric deficit and weight loss that semaglutide drives. Significant weight loss without testosterone support often produces lean mass loss alongside fat loss -- enclomiphene prevents the testosterone decline that drives this.
Component 1: Semaglutide
Standard titration: 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg, titrating to 1.7-2.4 mg at therapeutic dose. Some users run lower doses (0.5-1.0 mg) in conjunction with the other compounds, finding the appetite suppression at lower semaglutide doses is sufficient when combined with the metabolic effects of tesamorelin.
Tirzepatide is an alternative with stronger average weight loss -- protocol is comparable.
Component 2: Tesamorelin
1-2 mg subcutaneous daily at bedtime on an empty stomach. FDA-approved for visceral fat reduction -- this is its primary role in the Hollywood Stack. Preserves and builds lean mass through IGF-1 elevation while semaglutide drives caloric deficit.
Some users substitute ipamorelin 200-300 mcg plus CJC-1295 100-200 mcg twice or three times daily. Both approaches work -- tesamorelin is simpler (once daily) and has stronger visceral fat data; ipamorelin plus CJC-1295 has a more pulsatile GH pattern.
Component 3: Enclomiphene
25 mg oral daily or 12.5 mg twice daily. Prevents the testosterone decline that accompanies significant weight loss and caloric deficit. Critical for preserving the muscle protein synthesis and metabolic rate that testosterone supports. Without HPG axis support, rapid weight loss on semaglutide frequently drives testosterone down -- sometimes significantly.
This stack requires the most comprehensive lab monitoring of any protocol on MyProtocolStack. Monitoring frequency: baseline, 6 weeks, 12 weeks, 6 months.
IGF-1: Primary GH axis marker. Target 200-310 ng/mL. Draw fasted, morning, 24-36 hours post-tesamorelin dose.
Total testosterone, free testosterone, LH, FSH, SHBG: Full HPG axis panel. Enclomiphene should raise LH and total testosterone -- if it is not, reassess dose. Watch free testosterone specifically -- semaglutide-driven weight loss raises SHBG initially which can paradoxically lower free T despite rising total T.
Estradiol (E2): Enclomiphene raises testosterone which converts to estradiol. Target 20-40 pg/mL for men. Watch for estradiol climbing above 45-50 pg/mL with symptoms.
HbA1c and fasting glucose: Tesamorelin can raise fasting glucose; semaglutide lowers it. Net effect is usually neutral to beneficial but must be monitored. If glucose rises, semaglutide dose may need adjustment upward.
ApoB and lipid panel: Semaglutide should drive ApoB down. Tesamorelin reduces triglycerides through visceral fat reduction. Track every 12 weeks.
Liver enzymes (ALT, AST, GGT): Semaglutide improves fatty liver -- watch ALT fall. Tesamorelin is hepatically metabolized -- baseline liver function is important context.
Prolactin: Enclomiphene protocol baseline -- elevated prolactin can blunt LH response and explain why enclomiphene does not work as expected.
Body weight: 10-18% reduction typical at therapeutic semaglutide dose with full titration.
Body composition: Lean mass preservation or modest gain (tesamorelin plus enclomiphene combination prevents the lean mass loss typical of GLP-1 alone). DEXA or InBody assessment recommended at baseline and 12 weeks.
IGF-1: Rise of 30-60% above baseline at therapeutic tesamorelin dose.
Testosterone: Stable or rising with enclomiphene. LH should increase 40-80% above baseline.
ApoB: Reduction of 10-20 mg/dL. Triglycerides: reduction of 20-40%.
Is this stack appropriate for women?
The semaglutide and tesamorelin components are appropriate for women. Enclomiphene is primarily prescribed for men -- women have different HPG axis physiology. Women on the Hollywood Stack typically substitute hormonal support appropriate for their specific situation (discussed with their prescribing physician).
What is the cost of the Hollywood Stack?
Semaglutide: $150-400/month compounded. Tesamorelin: $200-500/month compounded. Enclomiphene: $75-150/month compounded. Total: approximately $400-1,000/month depending on pharmacy and dose.
Do all three compounds need to be started simultaneously?
Most practitioners recommend starting semaglutide first to establish GI tolerance, then adding tesamorelin at week 4-6, then adding enclomiphene at week 6-8. This staggered approach makes it easier to identify which compound is driving any side effects.
Can BPC-157 be added to manage GLP-1 nausea?
Yes -- BPC-157 250-500 mcg daily is a common addition specifically to manage semaglutide or tirzepatide nausea. Add BPC-157 when nausea appears, not preemptively.
Is there a risk of too much IGF-1 with tesamorelin plus semaglutide?
GLP-1 medications can modestly suppress IGF-1. The net effect of tesamorelin plus semaglutide is usually a meaningful IGF-1 rise (tesamorelin effect) that is slightly attenuated versus tesamorelin alone (GLP-1 suppression). Monitor IGF-1 at 6-8 weeks and adjust tesamorelin dose if needed to stay in the 200-310 ng/mL range.
The information in this article is for educational purposes only. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any peptide protocol.
Written by Ryan -- Founder, MyProtocolStack. Last Updated: April 2026.
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers -- not generic charts.
Start Free →